Cerenome, Inc. (CNSY) - Total Liabilities
Based on the latest financial reports, Cerenome, Inc. (CNSY) has total liabilities worth $8.57 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CNSY defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Cerenome, Inc. - Total Liabilities Trend (1998–2025)
This chart illustrates how Cerenome, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check Cerenome, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Cerenome, Inc. Competitors by Total Liabilities
The table below lists competitors of Cerenome, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
NASDAQ:AHMA
|
USA | $3.58 Million |
|
Lagnam Spintex Limited
NSE:LAGNAM
|
India | Rs4.36 Billion |
|
Kordsa Global Endustriyel Iplik ve Kord Bezi Sanayi ve Ticaret AS
IS:KORDS
|
Turkey | TL26.60 Billion |
|
Jupiter Energy Ltd
AU:JPR
|
Australia | AU$25.00 Million |
|
Pegasus Heights Bhd
KLSE:4464
|
Malaysia | RM7.62 Million |
|
Sungchang Autotech Co. Ltd
KQ:080470
|
Korea | ₩125.03 Billion |
|
CNFinance Holdings Ltd
NYSE:CNF
|
USA | $6.67 Billion |
|
Excel Realty N Infra Limited
NSE:EXCEL
|
India | Rs28.93 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Cerenome, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cerenome, Inc. assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cerenome, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cerenome, Inc. (1998–2025)
The table below shows the annual total liabilities of Cerenome, Inc. from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.33 Million | -20.88% |
| 2024-12-31 | $15.58 Million | +22.35% |
| 2023-12-31 | $12.74 Million | -26.90% |
| 2022-12-31 | $17.42 Million | +56.32% |
| 2021-12-31 | $11.14 Million | +22.82% |
| 2020-12-31 | $9.07 Million | -58.88% |
| 2019-12-31 | $22.07 Million | +17.60% |
| 2018-12-31 | $18.77 Million | +0.81% |
| 2017-12-31 | $18.61 Million | -21.20% |
| 2016-12-31 | $23.62 Million | -46.82% |
| 2014-12-31 | $44.42 Million | +14.11% |
| 2013-12-31 | $38.93 Million | +5.80% |
| 2012-12-31 | $36.80 Million | -11.52% |
| 2011-12-31 | $41.59 Million | -4.34% |
| 2010-12-31 | $43.47 Million | +53.04% |
| 2009-12-31 | $28.41 Million | -14.76% |
| 2008-12-31 | $33.33 Million | +7.83% |
| 2007-12-31 | $30.91 Million | -13.38% |
| 2006-12-31 | $35.68 Million | +3.74% |
| 2005-12-31 | $34.40 Million | +172.18% |
| 2004-12-31 | $12.64 Million | -4.12% |
| 2003-12-31 | $13.18 Million | -1.08% |
| 2002-12-31 | $13.32 Million | +186.11% |
| 2001-12-31 | $4.66 Million | +58.73% |
| 2000-12-31 | $2.93 Million | -74.97% |
| 1999-12-31 | $11.72 Million | +1185.31% |
| 1998-12-31 | $912.00K | -- |
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more